While direct clinical evidence for the use of ApoA-I mimetic peptides in PD is still emerging, animal models of PD have shown that these peptides can reduce peritoneal inflammation and oxidative stress, decrease the MMT of peritoneal mesothelial cells, and slow the progression of peritoneal fibrosis [122]. Here, APOA1 is linked to Peritoneal Fibrosis.